Pancreatic Acinar Cell Carcinoma clinical trials at UCSF
1 research study open to eligible people
Pancreatic acinar cell carcinoma is a type of cancer in the pancreas. UCSF is conducting trials to understand the effects of a three-drug chemotherapy for patients with BRCA1/2 or PALB2-associated pancreatic cancer. Researchers are assessing this treatment option to advance second-line therapies.
PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
open to eligible people ages 18 years and up
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
San Francisco, California and other locations
Our lead scientists for Pancreatic Acinar Cell Carcinoma research studies include Andrew H. Ko.
Last updated: